Novo commits $200 million to the World Diabetes Foundation

Nov 11 (Reuters) – Novo Nordisk said on Wednesday it will commit $200 million to the World Diabetes Foundation ​over 10 years starting 2027, ‌supporting the organization’s work to strengthen diabetes prevention and care in low- and middle-income countries. Here are some details: • The commitment, which ‌lasts ​until 2036, will give ⁠WDF greater certainty ⁠to plan long term, build on its partnerships, and scale regional and global responses to the growing burden ​of diabetes, the company said • The pledge “recognizes our work over 25 ⁠years to support ⁠people living with diabetes and ​related non-communicable diseases in low- and middle-income ​countries,” said Leif Jensen, managing director ‌of the World Diabetes Foundation • About 830 million people worldwide have diabetes, according to the World Health Organization • ⁠Novo is looking to recover ground lost to US rival Eli Lilly in the diabetes ⁠and ‌obesity drugs race, with Ozempic ⁠and Wegovy leading its ​charge • ‌Earlier this month, Novo raised ​its 2026 ⁠outlook for the third time this year as quarterly sales of its Wegovy pill for weight-loss beat forecasts (Reporting by Christy Santhosh in Bengaluru; Editing by ​Vijay Kishore)